Similar articles for PMID: 34330805

Year	Number of Results
2006	1
2007	4
2009	1
2011	1
2012	3
2013	2
2014	1
2015	1
2016	5
2017	15
2018	19
2019	20
2020	32
2021	22
2022	24

1

Immune Checkpoint Inhibitor-Related Adverse Effects and ¹⁸F-FDG PET/CT Findings.

Schierz JH, Sarikaya I, Wollina U, Unger L, Sarikaya A. Schierz JH, et al. J Nucl Med Technol. 2021 Dec;49(4):324-329. doi: 10.2967/jnmt.121.262151. Epub 2021 Jul 30. J Nucl Med Technol. 2021. PMID: 34330805 Review.

2

Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.

Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, Briganti A, Montorsi F, Alessi A, Necchi A. Marandino L, et al. Eur Urol Focus. 2021 Sep;7(5):1092-1099. doi: 10.1016/j.euf.2020.10.003. Epub 2020 Nov 7. Eur Urol Focus. 2021. PMID: 33172772

3

Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging.

Sachpekidis C, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Q J Nucl Med Mol Imaging. 2022 Sep;66(3):245-254. doi: 10.23736/S1824-4785.22.03453-7. Epub 2022 May 25. Q J Nucl Med Mol Imaging. 2022. PMID: 35612369 Free article.

4

The value of ¹⁸F-FDG PET/CT for predicting or monitoring immunotherapy response in patients with metastatic melanoma: a systematic review and meta-analysis.

Ayati N, Sadeghi R, Kiamanesh Z, Lee ST, Zakavi SR, Scott AM. Ayati N, et al. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):428-448. doi: 10.1007/s00259-020-04967-9. Epub 2020 Jul 29. Eur J Nucl Med Mol Imaging. 2021. PMID: 32728798 Review.

5

Interpretation of 2-[¹⁸F]FDG PET/CT in Hodgkin lymphoma patients treated with immune checkpoint inhibitors.

Manson G, Lemchukwu AC, Mokrane FZ, Lopci E, Aide N, Vercellino L, Houot R, Dercle L. Manson G, et al. Eur Radiol. 2022 Sep;32(9):6536-6544. doi: 10.1007/s00330-022-08669-8. Epub 2022 Mar 28. Eur Radiol. 2022. PMID: 35344061 Free article. Review.

6

Diagnostic impact of ¹⁸F-FDG PET/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy.

Tatar G, Alçin G, Sengul Samanci N, Erol Fenercioglu Ö, Beyhan E, Cermik TF. Tatar G, et al. Clin Transl Oncol. 2022 Oct;24(10):1903-1913. doi: 10.1007/s12094-022-02840-9. Epub 2022 May 20. Clin Transl Oncol. 2022. PMID: 35594002

7

Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo¹⁸F-FDG-PET.

Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, Weide B, Martella M, Gonzalez-Menendez I, Campi C, Sambuceti G, Seith F, Quintanilla-Martinez L, Garbe C, Pfannenberg C, Röcken M, la Fougere C, Pichler BJ, Kneilling M. Schwenck J, et al. Theranostics. 2020 Jan 1;10(2):925-937. doi: 10.7150/thno.35989. eCollection 2020. Theranostics. 2020. PMID: 31903160 Free PMC article.

8

FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment.

Iravani A, Osman MM, Weppler AM, Wallace R, Galligan A, Lasocki A, Hunter MO, Akhurst T, Hofman MS, Lau PKH, Kee D, Au-Yeung G, Sandhu S, Hicks RJ. Iravani A, et al. Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2776-2786. doi: 10.1007/s00259-020-04815-w. Epub 2020 Apr 21. Eur J Nucl Med Mol Imaging. 2020. PMID: 32338306

9

Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.

Hribernik N, Huff DT, Studen A, Zevnik K, Klaneček Ž, Emamekhoo H, Škalic K, Jeraj R, Reberšek M. Hribernik N, et al. Eur J Nucl Med Mol Imaging. 2022 May;49(6):1857-1869. doi: 10.1007/s00259-021-05650-3. Epub 2021 Dec 27. Eur J Nucl Med Mol Imaging. 2022. PMID: 34958422 Free PMC article.

10

Interim [¹⁸F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma.

Sachpekidis C, Kopp-Schneider A, Pan L, Papamichail D, Haberkorn U, Hassel JC, Dimitrakopoulou-Strauss A. Sachpekidis C, et al. Eur J Nucl Med Mol Imaging. 2021 Jun;48(6):1932-1943. doi: 10.1007/s00259-020-05137-7. Epub 2020 Dec 18. Eur J Nucl Med Mol Imaging. 2021. PMID: 33336264 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed